Abstract
The parenteral controlled delivery of acid-labile drugs (e.g., proteins) is difficult, because the standard polymer poly(lactic-co-glycolic acid) used to control drug release upon parenteral administration degrades into shorter chain acids, creating acidic microclimates. Lipid implants do not show this disadvantage. The objective of this article is to give an overview on the present state of the art and to highlight the advantages and drawbacks of the different types of systems reported in the literature. The major preparation techniques for lipid implants, underlying mass transport mechanisms, biocompatibility and in vivo performance of the most interesting systems are described. Lipid implants offer a great potential as parenteral controlled drug delivery systems, especially for protein-based drugs. A broad spectra of release patterns can be provided and acidic microclimates avoided.
Notes
Koennings S, Sapin A, Blunk T, et al. Towards controlled release of BDNF – manufacturing strategies for protein-loaded lipid implants and biocompatibility evaluation in the brain. J Control Rel 2007;119:163-72 Koennings S, Sapin A, Blunk T, et al. Towards controlled release of BDNF – manufacturing strategies for protein-loaded lipid implants and biocompatibility evaluation in the brain. J Control Rel 2007;119:163-72 Guse C, Koennings S, Kreye F, et al. Drug release from lipid-based implants: elucidation of the underlying mass transport mechanisms. Int J Pharm 2006;314:137-44 Guse C, Koennings S, Kreye F, et al. Drug release from lipid-based implants: elucidation of the underlying mass transport mechanisms. Int J Pharm 2006;314:137-44 Guse C, Koennings S, Blunk T, et al. Programmable implants – from pulsatile to controlled release. Int J Pharm 2006;314(2):161-9 Guse C, Koennings S, Blunk T, et al. Programmable implants – from pulsatile to controlled release. Int J Pharm 2006;314(2):161-9 Pongjanyakul T, Medlicott NJ, Tucker IG. Melted glyceryl palmitostearate (GPS) pellets for protein delivery. Int J Pharm 2004;271(1-2):53-62 Reitz C, Kleinebudde P. Solid lipid extrusion of sustained release dosage forms. Eur J Pharm Biopharm 2007;67(2):440-8 Guse C, Koennings S, Kreye F, et al. Drug release from lipid-based implants: elucidation of the underlying mass transport mechanisms. Int J Pharm 2006;314:137-44 Herrmann S, Winter G, Mohl S, et al. Mechanisms controlling protein release from lipidic implants: effects of PEG addition. J Control Rel 2007;118:161-8 Herrmann S, Mohl S, Siepmann F, et al. New insight into the role of polyethylene glycol acting as protein release modifier in lipidic implants. Pharm Res 2007;24(8):1527-37 Koennings S, Berie A, Tessmar J, et al. Influence of wettability and surface activity on release behavior of hydrophilic substances from lipid matrices. J Control Rel 2007;119(2):173-81 Guse C, Koennings S, Maschke A, et al. Biocompatibility and erosion behavior of implants made of triglycerides and blends with cholesterol and phospholipids. Int J Pharm 2006;314:153-60 Wang PY. Lipids as excipient in sustained release insulin implants. Int J Pharm 1989;54:223-30
![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})